WEED Canopy Growth Corp
- 4.250
- +0.090+2.16%
Canopy Growth Corp News
ATB Capital Markets Downgrades Canopy Growth(CGC.US) to Sell Rating, Cuts Target Price to $2.79
Canopy Growth (CGC) Was Downgraded to a Sell Rating at ATB Capital Markets
Canopy Growth Corp Price Target Cut to C$4.00/Share From C$6.00 by ATB Capital
Canopy Growth Corp. Price Target Cut to C$3.50/Share From C$5.00 by Canaccord Genuity
Analysts Offer Insights on Healthcare Companies: Novavax (NVAX), Regulus (RGLS) and Canopy Growth (CGC)
Piper Sandler Reaffirms Their Sell Rating on Canopy Growth (CGC)
Canopy Gwth Analyst Ratings
Piper Sandler Maintains Canopy Growth at Underweight, Cuts Price Target to US$2.00 on Weak Sales
Analysts Conflicted on These Healthcare Names: Cooper Co (COO), Canopy Growth (CGC) and BioMarin Pharmaceutical (BMRN)
Analysts Conflicted on These Healthcare Names: Canopy Growth (CGC), Ultragenyx Pharmaceutical (RARE) and Roivant Sciences (ROIV)
Canopy Growth Sell Rating Justified by Stagnant Sales, High Valuation, and Profitability Concerns
Canopy Growth's (TSE:WEED) US Invasion Falls Flat With Shareholders
Analysts Offer Insights on Healthcare Companies: Cigna (CI), Cogent Biosciences (COGT) and Canopy Growth (CGC)
Jefferies Sticks to Its Hold Rating for Canopy Growth (CGC)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bruker (BRKR), Canopy Growth (CGC) and Medtronic (MDT)
Piper Sandler Maintains Underweight on Canopy Gwth, Lowers Price Target to $3
Piper Sandler Sticks to Its Sell Rating for Canopy Growth (CGC)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Canopy Growth (CGC) and Vertex Pharmaceuticals (VRTX)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN) and Canopy Growth (CGC)
Canopy Growth's Stock Faces Sell Rating Amid Lower Sales, Regulatory Challenges, and Legal Risks
No Data
